1. Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization Associated with Pattern Dystrophy
- Author
-
Ilaria Zucchiatti, Francesco Bandello, Maurizio Battaglia Parodi, Pierluigi Iacono, Dimitrios Stylianos Kontadakis, Marialucia Cascavilla, Battaglia Parodi, M, Iacono, P, Cascavilla, M, Zucchiatti, I, Kontadakis, D, and Bandello, Francesco
- Subjects
Male ,Fovea Centralis ,medicine.medical_specialty ,Visual acuity ,genetic structures ,Bevacizumab ,Visual Acuity ,Angiogenesis Inhibitors ,Retinal Pigment Epithelium ,Antibodies, Monoclonal, Humanized ,Loading dose ,Ophthalmology ,medicine ,Humans ,Prospective Studies ,Intravitreal bevacizumab ,Prospective cohort study ,medicine.diagnostic_test ,business.industry ,Antibodies, Monoclonal ,Middle Aged ,Fluorescein angiography ,Choroidal Neovascularization ,eye diseases ,Vitreous Body ,Clinical trial ,Treatment Outcome ,Choroidal neovascularization ,Female ,sense organs ,Injections, Intraocular ,medicine.symptom ,business ,Follow-Up Studies ,medicine.drug - Abstract
PURPOSE: To assess the effects of intravitreal bevacizumab injections in the treatment of subfoveal choroidal neovascularization (CNV) associated with pattern dystrophy (PD) of the retinal pigment epithelium.METHODS: The study was a prospective, nonrandomized, open-label, interventional clinical trial in which 12 patients were prospectively enrolled. Patients with a diagnosis of PD complicated by subfoveal CNV were considered for the study. All patients underwent a complete ophthalmic examination, including ETDRS visual acuity measurement, electroretinogram, electrooculogram, optical coherence tomography, and fluorescein angiography. The treatment protocol began with a loading dose of three consecutive injections at 1-month intervals, followed by injections administered as needed, according to OCT parameters and angiographic features observed during a 24-month follow-up period. The number of eyes with a visual acuity loss of fewer than 15 letters (
- Published
- 2010